Shanhu Health Achieves 200% Annual Growth for Six Consecutive Years, Saving Tens of Millions per Clinical Trial Project

For a long time, new drug development has been under pressure due to high costs and lengthy cycles, with investments amounting to hundreds of millions of yuan facing up to a 75% risk of research failure. As study designs continue to innovate and management models become more precise and refined, the development of innovative drugs is undergoing positive adjustments and optimization, which also places higher demands on clinical research service providers. How to “enhance efficiency, reduce costs, and improve quality” for sponsors and CROs has become the focal point for service providers.

Shanghai Shanhu Health Technology Co., Ltd. (hereinafter referred to as "Shanhu Health"), as a clinical research service provider, has accurately grasped development trends and implemented its services within China's clinical trial industry, integrating the three major domains of GCP (Good Clinical Practice), GSP (Good Supply Practice), and GMP (Good Manufacturing Practice). This solutionSuccessfully facilitated the smooth launch of the PIONEER project led by Academician Zhong Nanshan’s team, and further implemented over 40 research projects with partners including AstraZeneca, GenSci, and Xinnowei within just nine months., effectively addressing the inherent challenges in clinical research.

In 2015, Shanhu Health was established in Zhangjiang, Shanghai, dedicated to providing high-quality digital products for clinical medical research. It currently has R&D centers, operational centers, and pharmaceutical warehousing centers in Suzhou, Guangzhou, Hangzhou, and Nanjing.

Over the past eight years, Shanhu Health has established a product matrix centered on clinical trial medications, addressing both online clinical needs and offline drug supply. The product portfolio includes IRTON (Ai’ertong), an Interactive Response Technology and Drug Supply Management System; IRTLite (Ai’erte), an Interactive Response Technology and Material Management System; EDCON (Ai’erkang), an Electronic Data Capture Platform; Clin-ON, an Electronic Clinical Outcome Assessment System; Clin-WMS, a Clinical Warehouse Management System; Depot-one, an expert solution for offline clinical supply chains; TRIAL X, an integrated digital intelligence platform for clinical trials; and IP4CAST, a drug forecasting model.

Shanhu Health Product Matrix

Among them, Shanhu Health’s core product, IRTON, has seen its features and applications further refined after six years of iteration and accumulation, with the latest version, IRTON 6.0, launched in 2022.IP4CAST, a drug forecasting model, is the latest product launched by Shanhu Health in 2023; within just 20 days of its release, it has already acquired more than 50 new customer groups.。

“Cost Reduction and Efficiency Enhancement” is a challenge that the clinical research industry must directly confront. Beyond the repeatedly emphasized resource integration and optimized allocation, the “hidden waste” of investigational medicinal products deserves greater attention. Data show that, on average, 30% of drugs in clinical trials go unused, with this figure exceeding 50% in large-scale, multicenter projects. Among more than 100 completed studies, Shanghai Shanhu Health Technology Co., Ltd. selected 43 typical samples and found that the actual drug utilization rate was only 52.3%.

The lP4CAST drug forecasting model leverages Monte Carlo algorithms and real-world study parameters, combined with tens of thousands of simulations, to accurately predict clinical supply chain plans. It employs deep machine learning algorithms to adjust clinical trial supplies in real time, accounting for multiple parameters such as patient dropout, temperature excursions, and expiration-related returns, thereby maximizing drug utilization from planning through production.

IP4CAST achieves optimal cost efficiency while ensuring drug supply. According to statistics from Shanhu Health,IP4CAST can increase drug utilization rates to 90%, achieve a prediction accuracy of 95%, reduce average drug wastage to 9%-11%, and save tens of millions per research project. Meanwhile, IP4CAST can also improve cross-departmental collaboration efficiency by 50% and supply chain efficiency by 30%.。

Clinical trials for new drugs involve numerous stages and span a long duration, ranging from production planning, product packaging, drug blinding, storage and transportation, and randomization to supply decision-making, data collection, and outcome assessment. Each stage is independent yet closely interconnected. Only by adopting an integrated mindset that consolidates resources and leverages core strengths can we efficiently address the challenges, bottlenecks, and critical constraints in clinical research, thereby truly meeting the needs across the entire lifecycle of new drug development.

By pioneering an integrated “clinical data + medication management” solution, Shanhu Health has become the first clinical research supplier to reap the benefits of this innovative approach.

Shanhu Health focuses on clinical drug and data management as its two main pillars, addressing the digital intelligence needs of the clinical demand side online and locking in the digital intelligence needs of the drug supply side offline, effectively forming“IRTON+EDCON+Clin-ON” Clinical Data Management, “IP4CAST+IRTON+Depot One+Clin-WMS” Clinical Drug ManagementIntegrated Solutions.

From the expansion of clinical data to the extension of drug management services, Shanhu Health has built “three lines of defense” for clinical research. First, accurate prediction and precision production: leveraging proprietary algorithms and big data analytics to determine drug demand, dynamically balancing medication usage plans, and improving drug utilization rates. Second, optimized and refined inventory management: reducing costs and increasing efficiency for teams through a one-stop product matrix. Third, enhanced subject compliance: ensuring that research centers administer medications on schedule and subjects take their medications as prescribed, thereby strengthening the scientific rigor of clinical trials.

In other words, this solution not only canFrom the “source,” it enables online modules for precise dosage prediction, customized protocol design, enhanced blinding protection, and patient adherence management; from the “end,” it addresses offline supply chain upgrades, drug packaging redesign, blinded labeling support, multi-temperature-zone warehousing, and long-term medication tracking.and other practical challenges, empowering and accelerating clinical research for new drugs.

Compared with developed countries, clinical research on new drugs in China started later and had weaker early accumulation. In recent years, driven by multiple factors such as technology, market demand, policy, and capital, China is getting closer to achieving the goal of "overtaking on a bend." As the steadfast backbone of Chinese innovative pharmaceutical companies, clinical research service providers have demonstrated strong developmental resilience and sustained growth potential, while shouldering increasingly heavy tasks and responsibilities. Amid adjustments in the global economic cycle, the industry is undergoing rapid iteration and survival of the fittest.

How Can Companies Achieve Rapid Growth and Capture Market Share in the Clinical Research Market During a Counter-Cyclical Period?

Shanhu Health’s answer is to precisely position itself in the market, deeply address industry demands, and persist in independent research and development.

Amid the current landscape, clinical research service providers are aggressively vying for market share through transformations, acquisitions, and mergers. Whether they can fully digest and integrate these changes remains to be tested by time. Meanwhile, Shanhu Health has not only responded to market demands with a comprehensive product matrix but also persisted in independent R&D and innovation. This approach has accelerated commercialization and continuously strengthened its growth momentum, thereby cultivating strategic resilience and inner composure that withstands any external turbulence.

The results are the most intuitive outcome.

Since its establishment in 2015,Shanhu Health has supported 1,000+ clinical studies, serving 2,000+ research centers, pharmaceutical companies, and CROs worldwide., many of which are large-scale international Phase III clinical trials. During the pandemic, Shanhu Health provided one-stop digital products and solutions for 80% of domestically produced COVID-19 vaccines and therapeutic drugs. Companies served by Shanhu Health include Hengrui Medicine, Fosun Pharma, BeiGene, Junshi Biosciences, PPC Jia Sheng, and Dima Biologics.Most customers have maintained high stickiness and a high repurchase rate for Shanhu Health's products.。

As a domestic clinical research enterprise, Shanhu Health deeply implements the “In China for Global” strategy, sparing no effort to help Chinese innovative pharmaceutical companies “go global” and smoothly conduct clinical studies worldwide. According to statistics,Shanhu Health’s projects have covered Asia, Oceania, North America, South America, Europe, and Africa, spanning 21 time zones and over 900 cities.。

In terms of performance,Shanhu Health’s sales in the first half of 2023 exceeded expectations by tens of millions, representing a 200% year-on-year increase; such rapid performance growth has been sustained since 2017.. With outstanding financial metrics such as annual revenue, repurchase rate, and gross profit margin, it secured tens of millions of yuan in Pre-A round financing from Sequoia China within just two years, followed by nearly 100 million yuan in A-round financing from Sequoia China, Sherpa Capital, and Zhongding Capital.